Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Revenue projections:

Revenue projections for DGX
Revenue projections for DGX

Investors may react cautiously to news that DGX's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.17900
forwardPE 17.64451
debtToEquity 82.71100
earningsGrowth 0.15500
revenueGrowth 0.09200
grossMargins 0.33268
operatingMargins 0.14162
trailingEps 9.06000
forwardEps 11.56167

DGX's current ratio of 1.179 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that DGX is financially well-prepared to meet its liabilities without difficulty.
With Quest Diagnostics Incorporated's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
DGX's elevated debt-to-equity ratio reflects substantial leverage, meaning the company relies heavily on borrowed funds. This could increase financial risk, particularly in times of economic uncertainty or if the company's profitability declines.
DGX's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in DGX's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for DGX
Price projections for DGX

Over time, price projections for Quest Diagnostics Incorporated have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in Quest Diagnostics Incorporated's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for DGX
Insider Transactions for DGX


24 sell transactions of DGX were recorded, with market price hovering near 184.68849817911783.There were 3 buy transactions of DGX stock, with market price at 170.3500010172526 per share.The insider transaction data shows no clear pattern or trend, making it difficult to draw any meaningful conclusions about the company's current direction based on this information.

Recommendation changes over time:

Recommendations trend for DGX
Recommendations trend for DGX


Analysts have maintained a buy bias for DGX, which could prompt investors to consider the stock as a viable investment. With this positive outlook, DGX is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.